Anti-viral drug should not be first choice in treating COVID-19

3 December 2022 - The most widely prescribed anti-viral drug in Australia, molnupiravir, should no longer be routinely given for ...

Read more →

Agenda for the December 2022 PBAC intracycle meeting

2 December 2022 - The agenda for the December 2022 PBAC intracycle meeting is now available. ...

Read more →

Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information

1 December 2022 - At a time when many Americans are clamouring for more transparency into prescription drug pricing, one ...

Read more →

Early breast cancer: indication of a minor additional clinical benefit of adjuvant therapy with olaparib

1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...

Read more →

‘Good news’ for Kiwi women as PHARMAC funds Utrogestan from today

1 December 2022 - The end of a decade long wait. ...

Read more →

Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection

1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...

Read more →

Takeda Korea's Kynteles SC wins insurance benefit

1 December 2022 - Takeda Pharmaceuticals Korea said Kynteles SC, an inflammatory bowel disease treatment, started to be covered by ...

Read more →

Lenvatinib mesylate in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

ICER publishes evidence report on fezolinetant for vasomotor symptoms associated with menopause

1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...

Read more →

Citius Pharmaceuticals announces US FDA acceptance of biologics license application of denileukin diftitox for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma

1 December 2022 - PDUFA target action date is 28 September 2023. ...

Read more →

FDA grants fast track designation to Nuvectis Pharma's NXP800 for the treatment of platinum-resistant, ARID1A mutated ovarian carcinoma

1 December 2022 - Nuvectis Pharma today announced that the US FDA has granted fast track designation to NXP800 for the ...

Read more →

Scynexis announces FDA approval of second indication for Brexafemme (ibrexafungerp) for reduction in incidence of recurrent vulvovaginal candidiasis

1 December 2022 - Approval is based on pivotal Phase 3 CANDLE data demonstrating statistically significant superiority of ibrexafungerp over ...

Read more →

Oncolytics Biotech receives FDA fast track designation for the treatment of advanced/metastatic pancreatic cancer

1 December 2022 - FDA fast rack designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective ...

Read more →

Aurinia announces the Great Britain marketing authorisation of Lupkynis (voclosporin) for the treatment of lupus nephritis

30 November 2022 - MHRA Approval follows European Commission marketing authorisation of Lupkynis to treat adults with active lupus nephritis in ...

Read more →

Reimbursed access to Bylvay (odevixibat) approved in France for patients with PFIC 1 & 2

30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...

Read more →

Innoviva announces FDA acceptance and priority review of new drug application for sulbactam-durlobactam

30 November 2022 - Sulbactam-durlobactam is a targeted antibiotic that was specifically designed to treat serious infections caused by Acinetobacter baumannii, ...

Read more →